Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$19.72 - $28.68 $5,916 - $8,604
300 Added 150.0%
500 $13,000
Q3 2023

Nov 09, 2023

SELL
$22.33 - $29.92 $3,617 - $4,847
-162 Reduced 44.75%
200 $4,000
Q2 2023

Aug 09, 2023

BUY
$20.96 - $26.99 $4,192 - $5,398
200 Added 123.46%
362 $9,000
Q1 2023

May 12, 2023

BUY
$20.58 - $27.89 $3,333 - $4,518
162 New
162 $3,000
Q2 2021

Aug 10, 2021

SELL
$32.94 - $56.62 $16,601 - $28,536
-504 Closed
0 $0
Q1 2021

May 12, 2021

SELL
$44.47 - $81.38 $4,447 - $8,138
-100 Reduced 16.56%
504 $27,000
Q4 2020

Feb 10, 2021

BUY
$32.49 - $61.88 $19,623 - $37,375
604 New
604 $30,000
Q2 2020

Aug 13, 2020

SELL
$19.49 - $28.11 $20,990 - $30,274
-1,077 Closed
0 $0
Q1 2020

May 13, 2020

SELL
$16.13 - $30.17 $27,711 - $51,832
-1,718 Reduced 61.47%
1,077 $26,000
Q4 2019

Feb 10, 2020

SELL
$20.78 - $29.99 $8,312 - $11,996
-400 Reduced 12.52%
2,795 $78,000
Q3 2019

Nov 12, 2019

BUY
$23.87 - $30.93 $76,264 - $98,821
3,195 New
3,195 $77,000
Q2 2019

Aug 09, 2019

SELL
$22.1 - $28.56 $6,188 - $7,996
-280 Closed
0 $0
Q1 2019

May 13, 2019

SELL
$12.0 - $25.76 $24,000 - $51,520
-2,000 Reduced 87.72%
280 $7,000
Q4 2018

Feb 06, 2019

BUY
$9.15 - $14.85 $20,862 - $33,858
2,280 New
2,280 $29,000
Q2 2018

Aug 14, 2018

SELL
$5.39 - $9.66 $232,168 - $416,094
-43,074 Closed
0 $0
Q1 2018

May 11, 2018

SELL
$5.44 - $6.97 $38,379 - $49,173
-7,055 Reduced 14.07%
43,074 $239,000
Q4 2017

Feb 09, 2018

BUY
$6.05 - $9.37 $283,987 - $439,827
46,940 Added 1471.93%
50,129 $327,000
Q3 2017

Nov 15, 2017

SELL
$7.81 - $8.77 $53,678 - $60,276
-6,873 Reduced 68.31%
3,189 $28,000
Q2 2017

Aug 14, 2017

BUY
N/A
10,062
10,062 $84,000

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.97B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.